Literature DB >> 14747579

Antiviral activity of distamycin A against vaccinia virus is the result of inhibition of postreplicative mRNA synthesis.

Steven S Broyles1, Marcia Kremer, Bruce A Knutson.   

Abstract

Distamycin A has been described as an inhibitor of the cellular pathogenesis of vaccinia virus in culture. Distamycin is an antibiotic that specifically targets the minor groove of DNA. We show here that distamycin is a potent inhibitor of vaccinia virus replication. Pulse-labeling experiments showed that most major late proteins failed to accumulate in the presence of the antibiotic. We characterized the effect of distamycin on vaccinia virus nucleic acid biosynthesis with the goal of determining the inhibitor's target. Early gene transcription was unaffected. DNA synthesis proceeded at normal rates, but DNA accumulated in large masses in the cytoplasm with no evidence of virion assembly. Transcription from the intermediate class promoter for the I1L gene was partially reduced by distamycin; however, transcription from the intermediate promoters for the three late transcription factor genes was severely inhibited. The accumulation of the late transcripts for the viral F17R and A10L genes also was severely impaired and was shown to be a direct inhibition of late promoter activity. These results indicate that inhibition of postreplicative intermediate and late transcription is the basis for inhibition of vaccinia virus by distamycin and indicate that DNA minor-groove ligands hold promise for effective anti-poxvirus drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747579      PMCID: PMC369444          DOI: 10.1128/jvi.78.4.2137-2141.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins.

Authors:  C F Wright; B W Oswald; S Dellis
Journal:  J Biol Chem       Date:  2001-08-23       Impact factor: 5.157

2.  Transcription factor YY1 is a vaccinia virus late promoter activator.

Authors:  S S Broyles; X Liu; M Zhu; M Kremer
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

Review 3.  Complexes of the minor groove of DNA.

Authors:  B H Geierstanger; D E Wemmer
Journal:  Annu Rev Biophys Biomol Struct       Date:  1995

4.  Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene.

Authors:  S Venkatesan; B M Baroudy; B Moss
Journal:  Cell       Date:  1981-09       Impact factor: 41.582

5.  Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus.

Authors:  R C Condit; A Motyczka
Journal:  Virology       Date:  1981-08       Impact factor: 3.616

Review 6.  Vaccinia virus transcription.

Authors:  Steven S Broyles
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

7.  Purification of a factor required for transcription of vaccinia virus early genes.

Authors:  S S Broyles; L Yuen; S Shuman; B Moss
Journal:  J Biol Chem       Date:  1988-08-05       Impact factor: 5.157

8.  Vaccinia virus produces late mRNAs by discontinuous synthesis.

Authors:  C Bertholet; E Van Meir; B ten Heggeler-Bordier; R Wittek
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

9.  Discontinuous transcription or RNA processing of vaccinia virus late messengers results in a 5' poly(A) leader.

Authors:  B Schwer; P Visca; J C Vos; H G Stunnenberg
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

View more
  8 in total

1.  Vaccinia virus intermediate and late promoter elements are targeted by the TATA-binding protein.

Authors:  Bruce A Knutson; Xu Liu; Jaewook Oh; Steven S Broyles
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors.

Authors:  Chad Myskiw; Yvon Deschambault; Kristel Jefferies; Runtao He; Jingxin Cao
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

3.  HPV episome levels are potently decreased by pyrrole-imidazole polyamides.

Authors:  Terri G Edwards; Kevin J Koeller; Urszula Slomczynska; Kam Fok; Michael Helmus; James K Bashkin; Chris Fisher
Journal:  Antiviral Res       Date:  2011-06-02       Impact factor: 5.970

4.  Molecular docking of intercalators and groove-binders to nucleic acids using Autodock and Surflex.

Authors:  Patrick A Holt; Jonathan B Chaires; John O Trent
Journal:  J Chem Inf Model       Date:  2008-07-22       Impact factor: 4.956

5.  Therapeutic and prophylactic drugs to treat orthopoxvirus infections.

Authors:  Scott Parker; Lauren Handley; R Mark Buller
Journal:  Future Virol       Date:  2008-11       Impact factor: 1.831

6.  Effect of DNA groove binder distamycin A upon chromatin structure.

Authors:  Parijat Majumder; Dipak Dasgupta
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

7.  Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease.

Authors:  Eslam B Elkaeed; Fadia S Youssef; Ibrahim H Eissa; Hazem Elkady; Aisha A Alsfouk; Mohamed L Ashour; Mahmoud A El Hassab; Sahar M Abou-Seri; Ahmed M Metwaly
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

8.  Minor groove binder distamycin remodels chromatin but inhibits transcription.

Authors:  Parijat Majumder; Amrita Banerjee; Jayasha Shandilya; Parijat Senapati; Snehajyoti Chatterjee; Tapas K Kundu; Dipak Dasgupta
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.